Glycogen Synthase Kinase-3 (GSK-3)–Targeted Therapy and Imaging
Mukesh K. Pandey and Timothy R. DeGrado
Theranostics 2016, Vol. 6, Issue 4

In a 2016 review about GSK-3 inhibitors, Pandey and DeGrado showed the enzime imaging studies, with the designe of inhibitor's, as a powerful instrument to study inhibitors that can selectively target
individual pathways and differentiate between the phosphorylated and non-phosphorylated forms of
GSK-3. These studies ca evaluate drugs candidates based on noninvasive imaging measurements
of the target-to-background ratios.

A recent Review: "Recent advances in understanding the cellular roles of GSK-3" Cormier KW and Woodgett JR. Recent advances in understanding the cellular roles of GSK-3 [version 1; referees: 3 approved] F1000Research 2017, 6(F1000 Faculty Rev):167 (doi: 10.12688/f1000research.10557.1),  showed some pathways to inactivate  the enzyme. I´m trying to find other unusual way to inactivate GSK-3 because of our research about lithium and Alzheimer´s Disease. We used lithium microdose. In this Review Woodget sayd "Besides exploring the regulation of GSK-3 through association with scaffolding proteins and phosphorylation at S9/21, recent findings have explored GSK-3 regulation by other post-translational modifications". I´m very interested in this issue.

Publication

Hy
I´m back in my posts of GSK3 and Lithium.
Our paper was publishied in PLOSone in 2015:

"Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease"
Nowadays we are study the pathways of lithium efficacy in our work.